Investing.com - Immunome (NASDAQ: IMNM) reported first quarter EPS of $-2.51, $1.72 worse than the analyst estimate of $-0.79. Revenue for the quarter came in at $1.03M versus the consensus estimate of $2.5M.
Immunome's stock price closed at $15.61. It is down -39.59% in the last 3 months and up 147.27% in the last 12 months.
Immunome saw positive EPS revisions and negative EPS revisions in the last 90 days. See Immunome's stock price’s past reactions to earnings here.
According to InvestingPro, Immunome's Financial Health score is "fair performance".
Check out Immunome's recent earnings performance, and Immunome's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar